Holen Sie sich die Stockscreener-App
2.85
1.04%
-0.03
Handel nachbörslich:
2.89
0.04
+1.40%
Schlusskurs vom Vortag:
$2.88
Offen:
$2.85
24-Stunden-Volumen:
1.96M
Relative Volume:
0.77
Marktkapitalisierung:
$260.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-1.7169
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
+22.84%
1M Leistung:
+48.44%
6M Leistung:
+159.09%
1J Leistung:
-41.24%
1-Tages-Spanne:
$2.77
$2.93
1-Wochen-Bereich:
$2.24
$3.08
52-Wochen-Spanne:
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Vergleichen Sie CABA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.85 | 263.42M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
A activityJuly 2025 Update & High Conviction Trade Alerts - Trung tâm Dự báo KTTV quốc gia
Evaluating Cabaletta Bio Inc. with trendline analysisJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - newser.com
Can Cabaletta Bio Inc. stock surprise with earnings upside2025 Price Targets & Daily Volume Surge Trade Alerts - Trung tâm Dự báo KTTV quốc gia
Cabaletta Bio Inc. stock trendline breakdownChart Signals & Consistent Profit Alerts - newser.com
Using flow based indicators on Cabaletta Bio Inc.2025 EndofYear Setup & Step-by-Step Swing Trade Plans - newser.com
Is Cabaletta Bio Inc a good long term investmentStock Watchlist Updates & Free Trading Psychology Coaching - earlytimes.in
Cabaletta Bio Inc. stock chart pattern explainedFed Meeting & Smart Money Movement Tracker - newser.com
Why Cabaletta Bio Inc. stock could rally in 2025July 2025 Review & Real-Time Chart Breakout Alerts - newser.com
How Cabaletta Bio Inc. stock reacts to bond yieldsTrade Exit Summary & Community Consensus Trade Signals - newser.com
Visualizing Cabaletta Bio Inc. stock with heatmapsMarket Weekly Review & Weekly Chart Analysis and Trade Guides - newser.com
Measuring Cabaletta Bio Inc.’s beta against major indices2025 Price Momentum & Verified Trade Idea Suggestions - newser.com
Can Cabaletta Bio Inc. hit a new high this monthVolume Spike & Real-Time Stock Price Movement Reports - newser.com
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.Watch List & Fast Entry Momentum Alerts - newser.com
Cabaletta Bio, Inc. Announces the Appointment of Steve Gavel as Chief Commercial Officer, Effective from October 14, 2025 - MarketScreener
Cabaletta Bio (CABA) Names Steve Gavel as Chief Commercial Officer - GuruFocus
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant - The Manila Times
275,000-option inducement: Cabaletta names Steve Gavel CCO to lead rese-cel strategy; BLA due 2027 - Stock Titan
Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning - MyChesCo
Cabaletta Bio Announces Public Offering of Common Stock and Warrants - MSN
Cabaletta Bio (CABA): Assessing Valuation After RESET-PV Trial Results Spark Investor Interest - Yahoo Finance
What candlestick patterns are forming on Cabaletta Bio Inc.2025 Dividend Review & Verified Entry Point Signals - newser.com
Tools to monitor Cabaletta Bio Inc. recovery probabilityEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Cabaletta Bio (NASDAQ:CABA) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at HC Wainwright - MarketBeat
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating By Investing.com - Investing.com Canada
Cabaletta Bio (CABA) Is Up 12.6% After CAR T Therapy Shows Early Success Without Preconditioning – Has the Bull Case Changed? - Yahoo Finance
Morning Market Movers: INTS, SHPH, CARM Spark Moves - RTTNews
Cabaletta Bio stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
HC Wainwright & Co. Reiterates Buy Rating for CABA with $16 Pric - GuruFocus
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating - Investing.com
Can Cabaletta Bio Inc. stock outperform in 2025 bull marketJuly 2025 Recap & Expert Curated Trade Ideas - newser.com
Will Cabaletta Bio Inc. benefit from macro trendsWeekly Trend Report & Smart Swing Trading Alerts - newser.com
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):